Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple-Drug cocktail for septic shock shows promise in small trial

NCT ID NCT06155812

Disease control Sponsor: University Medical Centre Maribor Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving three blood-pressure-raising drugs (norepinephrine, angiotensin II, and vasopressin) together early in septic shock works better than the usual stepwise approach. Researchers enrolled 79 adults with severe sepsis and low blood pressure despite fluids. They measured changes in renin levels, a marker of tissue blood flow, and survival. The goal is to find a faster way to restore circulation and reduce deaths in the ICU.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
norepinephrine, angiotensin II, and vasopressin (vasopressors)
What this could lead to
If successful, this approach could lead to better blood flow and survival for patients with septic shock, potentially becoming a new standard in intensive care.
What could go wrong
This is a small, early-phase trial (79 participants) comparing two strategies, so results may not apply broadly. The drugs can cause side effects like excessive blood pressure or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

79 people

The number who actually took part.

Started

Dec 2023

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥18 years). * Sepsis (an acute change in total Sequential Organ Failure Assessment (SOFA) score ≥2 points consequent to infection) with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level \>2 mmol/L despite adequate volume resuscitation (20-30ml/kg in 3 hours). * Vasopressor requirement of ≥0,15 μg/kg/min equivalent of norepinephrine base. * Patients are required to have central venous access and an arterial line present, and these are expected to remain present for at least the initial 72 hours of study. * Patients are required to have an urinary catheter present, and it is expected to remain present for at least the initial 72 hours of study. * Patients must have cardiac index (CI) \>2.3 L/min/m2 (measured by bedside echocardiography, pulse contour cardiac output (PiCCO) or Swan-Ganz catheter). Exclusion Criteria: * Death expected \<24 hours. * Pregnancy (suspected or confirmed). * Surgery expected for source of infection. * Inter-hospital transfer expected during first 72 hours of hospitalization. * Liver failure with a Model for End-Stage Liver Disease (MELD) score of ≥30. * Patients with acute mesenteric ischemia or a history of mesenteric ischemic. * Patients with Raynaud's phenomenon, systemic sclerosis or vasospastic disease. * Patients with active bleeding and an anticipated need (within 48 hours of initiation of the study) for transfusion of \>4 units of packed red blood cells. * Patients with a known allergy to mannitol. * Patients on veno-arterial (VA) ECMO.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Shock, septic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes insipidus toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Shock, septic

Contacts and locations

Locations

  • Medical intensive care unit UMC Maribor

    Maribor, 2000, Slovenia

  • University Hospital Centre Zagreb

    Zagreb, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.